427 / 1726
•
Elective dose including draining lymphatic system
•
Boost to regional pathologic nodes
•
Boost to primary tumor if brachytherapy is not feasible
•
Dose needed for tumor control to high for surrounding OAR
•
Reduction according to ALARA, as low as reasonably achievable
•
Dose constraints and DVH parameters help to balance between tumor
dose and OAR dose
EBRT for gyn cancer treatment